Scotiabank Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by Scotiabank from $558.00 to $660.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “sector outperform” rating on the pharmaceutical company’s stock. Scotiabank‘s price objective suggests a potential upside of 23.53% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on VRTX. Evercore boosted their price target on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a report on Wednesday, September 2nd. Royal Bank Of Canada raised their price objective on Vertex Pharmaceuticals from $576.00 to $600.00 and gave the stock an “outperform” rating in a research note on Tuesday. UBS Group lifted their price objective on shares of Vertex Pharmaceuticals from $615.00 to $640.00 and gave the stock a “buy” rating in a report on Tuesday. Rothschild & Co Redburn boosted their target price on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Leerink Partners began coverage on shares of Vertex Pharmaceuticals in a report on Monday, September 21st. They set an “outperform” rating and a $594.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $595.74.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock traded down $18.88 during trading hours on Tuesday, reaching $534.27. The company had a trading volume of 1,204,990 shares, compared to its average volume of 1,388,479. The company has a market capitalization of $135.60 billion, a P/E ratio of 31.06, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28. The stock’s fifty day simple moving average is $523.32 and its 200 day simple moving average is $479.96. Vertex Pharmaceuticals has a twelve month low of $403.16 and a twelve month high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The business had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the firm posted $4.80 EPS. The company’s revenue was up 11.8% compared to the same quarter last year. As a group, equities analysts expect that Vertex Pharmaceuticals will post 16.74 earnings per share for the current year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in VRTX. MADDEN SECURITIES Corp acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at $26,000. Meeder Asset Management Inc. acquired a new position in Vertex Pharmaceuticals during the second quarter worth about $26,000. Community Financial Services Group LLC acquired a new position in Vertex Pharmaceuticals during the second quarter worth about $26,000. Elevation Wealth Partners LLC raised its position in Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 28 shares in the last quarter. Finally, Pingora Partners LLC bought a new stake in Vertex Pharmaceuticals in the second quarter worth about $32,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue increased 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Several analysts raised their price targets after the earnings release. RBC lifted its target to $600 with an “outperform” rating, Wells Fargo raised its target to $650 with an “overweight” rating, Cantor Fitzgerald increased its target to $619 with an “overweight” rating, and Stifel raised its target to $563 while maintaining a “hold” rating. Wells Fargo analyst update
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $13.2 billion-$13.3 billion and highlighted continued portfolio diversification, pipeline progress, and the completed acquisition of Crinetics Pharmaceuticals. Vertex third-quarter results
• Neutral Sentiment: The company’s outlook is broadly in line with Wall Street’s $13.3 billion revenue estimate, limiting the positive impact of the guidance increase. Investors will focus on whether newer launches can offset the eventual transition within the cystic fibrosis business.
• Negative Sentiment: Third-quarter adjusted earnings of $4.76 per share fell short of consensus estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Vertex misses third-quarter earnings estimates
• Negative Sentiment: Higher investment in new product launches and the Crinetics transaction kept profit growth from matching revenue growth, creating concern that elevated spending could weigh on near-term margins.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.